SCHEMBL6680199

SCHEMBL6680199

COc1ccc(C(CC(=O)c2ccccc2)S(=O)(=O)O)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.76
ALDH1A1 P00352 4/20 0.76
RAB9A P51151 4/20 0.76
SMN1; SMN2 Q16637 2/20 0.76
TDP1 Q9NUW8 1/20 0.76
MAPT P10636 3/20 0.70
LMNA P02545 2/20 0.70
L3MBTL1 Q9Y468 2/20 0.68
GAA P10253 2/20 0.55
HTT P42858 2/20 0.55
KMT2A Q03164 2/20 0.55
KDM4E B2RXH2 1/20 0.55
MEN1 O00255 1/20 0.55
MGAM O43451 1/20 0.52
SI P14410 1/20 0.52
MGAM2 Q2M2H8 1/20 0.52
HSD11B1 P28845 1/20 0.51
PDE4A P27815 4/20 0.50
PDE4B Q07343 4/20 0.50
PDE4C Q08493 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6674039 0.94 ALDH1A1 (0.68) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL7253273 0.93 ALDH1A1 (0.67) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL22014331 0.85 TSHR (0.56) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL6677049 0.85 TSHR (0.56) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL22014067 0.85 TSHR (0.56) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL6677047 0.84 NPC1 (0.63) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL29160472 0.84 ALDH1A1 (0.90) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL6676805 0.84 NPC1 (0.55) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL6673825 0.84 TSHR (0.55) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1
SCHEMBL3242243 0.82 ALDH1A1 (0.67) NPC1ALDH1A1RAB9ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1204636-B1 3-OXOPROPANE-1-SULPHONIC ACIDS AND SULPHONATES DSM IP ASSETS BV (NL) 2004-10-27 EP claimed
US-6639103-B1 Enantiomerically enriched forms; resolving amino functiona-lized enantiomers DSM N.V. (NL) 2003-10-28 US claimed
EP-1204636-A1 3-OXOPROPANE-1-SULPHONIC ACIDS AND SULPHONATES DSM N.V. (NL) 2002-05-15 EP claimed
WO-2001014327-A1 3-OXOPROPANE-1-SULPHONIC ACIDS AND SULPHONATES DSM N.V. (NL) 2001-03-01 WO claimed
US-20120029197-A1 Method for Preparing Sulfur-Containing Compounds THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2012-02-02 US disclosed
US-20120029197-A1 Method for Preparing Sulfur-Containing Compounds THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2012-02-02 US disclosed
WO-2010066450-A1 A METHOD FOR PREPARING SULFUR-CONTAINING COMPOUNDS THE ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) 2010-06-17 WO disclosed
EP-1204636-B1 3-OXOPROPANE-1-SULPHONIC ACIDS AND SULPHONATES DSM IP ASSETS BV (NL) 2004-10-27 EP disclosed
US-6639103-B1 Enantiomerically enriched forms; resolving amino functiona-lized enantiomers DSM N.V. (NL) 2003-10-28 US disclosed
EP-1204636-A1 3-OXOPROPANE-1-SULPHONIC ACIDS AND SULPHONATES DSM N.V. (NL) 2002-05-15 EP disclosed
WO-2001014327-A1 3-OXOPROPANE-1-SULPHONIC ACIDS AND SULPHONATES DSM N.V. (NL) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029197-A1 Method for Preparing Sulfur-Containing Compounds SULT1E1, SULT1A1, TST NPC1 2488/4885ALDH1A1 195/4885RAB9A 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.